instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cachexia'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | DENOSUMAB, NIVOLUMAB, PACLITAXEL, PALBOCICLIB, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY | 33191899 | 17,820,365 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | DENOSUMAB, NIVOLUMAB, PACLITAXEL, PALBOCICLIB, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY | 33191899 | 17,820,365 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Jaundice cholestatic'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | DENOSUMAB, NIVOLUMAB, PACLITAXEL, PALBOCICLIB, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY | 33191899 | 17,820,365 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Osteomalacia'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | DENOSUMAB, NIVOLUMAB, PACLITAXEL, PALBOCICLIB, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY | 33191899 | 17,820,365 | 2021-02 |
What was the administration route of drug 'CALCIUM CITRATE'? | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | Oral | DrugAdministrationRoute | CC BY | 33191899 | 19,139,574 | 2021-02 |
What was the administration route of drug 'CALCIUM GLUCONATE'? | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33191899 | 19,139,574 | 2021-02 |
What was the administration route of drug 'SODIUM PHOSPHATE'? | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33191899 | 19,139,574 | 2021-02 |
What was the dosage of drug 'CALCIUM CITRATE'? | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | 3.8 G (+4 DAYS) | DrugDosageText | CC BY | 33191899 | 19,139,574 | 2021-02 |
What was the outcome of reaction 'Blood parathyroid hormone decreased'? | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | Recovering | ReactionOutcome | CC BY | 33191899 | 19,139,574 | 2021-02 |
What was the outcome of reaction 'Blood phosphorus increased'? | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | Recovering | ReactionOutcome | CC BY | 33191899 | 19,139,574 | 2021-02 |
What was the outcome of reaction 'Death'? | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | Fatal | ReactionOutcome | CC BY | 33191899 | 17,820,365 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anuria'. | Hypertonic saline-induced urolithiasis presenting as acute renal failure in a child with traumatic brain injury: A case report.
We report the case of a 4 year old female with severe traumatic brain injury who developed bilateral obstructing ureteral stones after hypertonic saline treatment. She developed calcium phosph... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-ND | 33194552 | 19,598,806 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hydronephrosis'. | Hypertonic saline-induced urolithiasis presenting as acute renal failure in a child with traumatic brain injury: A case report.
We report the case of a 4 year old female with severe traumatic brain injury who developed bilateral obstructing ureteral stones after hypertonic saline treatment. She developed calcium phosph... | LEVETIRACETAM, SODIUM ACETATE, SODIUM CHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33194552 | 19,605,126 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nephrolithiasis'. | Hypertonic saline-induced urolithiasis presenting as acute renal failure in a child with traumatic brain injury: A case report.
We report the case of a 4 year old female with severe traumatic brain injury who developed bilateral obstructing ureteral stones after hypertonic saline treatment. She developed calcium phosph... | LEVETIRACETAM, SODIUM ACETATE, SODIUM CHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33194552 | 19,506,348 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Hypertonic saline-induced urolithiasis presenting as acute renal failure in a child with traumatic brain injury: A case report.
We report the case of a 4 year old female with severe traumatic brain injury who developed bilateral obstructing ureteral stones after hypertonic saline treatment. She developed calcium phosph... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-ND | 33194552 | 19,598,806 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ureterolithiasis'. | Hypertonic saline-induced urolithiasis presenting as acute renal failure in a child with traumatic brain injury: A case report.
We report the case of a 4 year old female with severe traumatic brain injury who developed bilateral obstructing ureteral stones after hypertonic saline treatment. She developed calcium phosph... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-ND | 33194552 | 19,598,806 | 2021-01 |
What was the outcome of reaction 'Hydronephrosis'? | Hypertonic saline-induced urolithiasis presenting as acute renal failure in a child with traumatic brain injury: A case report.
We report the case of a 4 year old female with severe traumatic brain injury who developed bilateral obstructing ureteral stones after hypertonic saline treatment. She developed calcium phosph... | Recovered | ReactionOutcome | CC BY-NC-ND | 33194552 | 19,605,126 | 2021-01 |
What was the outcome of reaction 'Nephrolithiasis'? | Hypertonic saline-induced urolithiasis presenting as acute renal failure in a child with traumatic brain injury: A case report.
We report the case of a 4 year old female with severe traumatic brain injury who developed bilateral obstructing ureteral stones after hypertonic saline treatment. She developed calcium phosph... | Recovered | ReactionOutcome | CC BY-NC-ND | 33194552 | 19,506,348 | 2021-01 |
What was the outcome of reaction 'Ureterolithiasis'? | Hypertonic saline-induced urolithiasis presenting as acute renal failure in a child with traumatic brain injury: A case report.
We report the case of a 4 year old female with severe traumatic brain injury who developed bilateral obstructing ureteral stones after hypertonic saline treatment. She developed calcium phosph... | Recovered | ReactionOutcome | CC BY-NC-ND | 33194552 | 19,598,806 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Complete response of penile mycosis fungoides with systemic brentuximab therapy.
Mycosis fungoides with penile involvement is extremely rare. Previous reports have shown successful treatment with imiquimod or a combination of beam radiation and chemotherapy. We present a patient with mycosis fungoides and penile involv... | IMIQUIMOD | DrugsGivenReaction | CC BY-NC-ND | 33194554 | 20,768,881 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Complete response of penile mycosis fungoides with systemic brentuximab therapy.
Mycosis fungoides with penile involvement is extremely rare. Previous reports have shown successful treatment with imiquimod or a combination of beam radiation and chemotherapy. We present a patient with mycosis fungoides and penile involv... | GEMCITABINE, PRALATREXATE | DrugsGivenReaction | CC BY-NC-ND | 33194554 | 19,598,815 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Urine flow decreased'. | Complete response of penile mycosis fungoides with systemic brentuximab therapy.
Mycosis fungoides with penile involvement is extremely rare. Previous reports have shown successful treatment with imiquimod or a combination of beam radiation and chemotherapy. We present a patient with mycosis fungoides and penile involv... | IMIQUIMOD | DrugsGivenReaction | CC BY-NC-ND | 33194554 | 20,768,881 | 2021-01 |
What was the administration route of drug 'IMIQUIMOD'? | Complete response of penile mycosis fungoides with systemic brentuximab therapy.
Mycosis fungoides with penile involvement is extremely rare. Previous reports have shown successful treatment with imiquimod or a combination of beam radiation and chemotherapy. We present a patient with mycosis fungoides and penile involv... | Topical | DrugAdministrationRoute | CC BY-NC-ND | 33194554 | 19,627,157 | 2021-01 |
What was the dosage of drug 'BRENTUXIMAB VEDOTIN'? | Complete response of penile mycosis fungoides with systemic brentuximab therapy.
Mycosis fungoides with penile involvement is extremely rare. Previous reports have shown successful treatment with imiquimod or a combination of beam radiation and chemotherapy. We present a patient with mycosis fungoides and penile involv... | 1.8 MILLIGRAM/KILOGRAM | DrugDosageText | CC BY-NC-ND | 33194554 | 19,567,167 | 2021-01 |
What was the outcome of reaction 'Condition aggravated'? | Complete response of penile mycosis fungoides with systemic brentuximab therapy.
Mycosis fungoides with penile involvement is extremely rare. Previous reports have shown successful treatment with imiquimod or a combination of beam radiation and chemotherapy. We present a patient with mycosis fungoides and penile involv... | Recovered | ReactionOutcome | CC BY-NC-ND | 33194554 | 20,768,881 | 2021-01 |
What was the outcome of reaction 'Drug ineffective'? | Complete response of penile mycosis fungoides with systemic brentuximab therapy.
Mycosis fungoides with penile involvement is extremely rare. Previous reports have shown successful treatment with imiquimod or a combination of beam radiation and chemotherapy. We present a patient with mycosis fungoides and penile involv... | Fatal | ReactionOutcome | CC BY-NC-ND | 33194554 | 19,627,157 | 2021-01 |
What was the outcome of reaction 'Urine flow decreased'? | Complete response of penile mycosis fungoides with systemic brentuximab therapy.
Mycosis fungoides with penile involvement is extremely rare. Previous reports have shown successful treatment with imiquimod or a combination of beam radiation and chemotherapy. We present a patient with mycosis fungoides and penile involv... | Recovering | ReactionOutcome | CC BY-NC-ND | 33194554 | 20,768,881 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Maternal exposure before pregnancy'. | A Pharmacoepidemiologic Approach to Evaluate Real-world Effectiveness of Hormonal Contraceptives in the Presence of Drug-drug Interactions.
Accurate estimation of conception is critical in the assessment of the effects of drugs used during pregnancy or to prevent pregnancy. In a novel application, we studied the effect... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33196560 | 18,620,305 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pregnancy on contraceptive'. | A Pharmacoepidemiologic Approach to Evaluate Real-world Effectiveness of Hormonal Contraceptives in the Presence of Drug-drug Interactions.
Accurate estimation of conception is critical in the assessment of the effects of drugs used during pregnancy or to prevent pregnancy. In a novel application, we studied the effect... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33196560 | 18,620,305 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, ETOPOSIDE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN, PACLITAXEL, PANITUMUMAB | DrugsGivenReaction | CC BY-NC | 33197299 | 18,711,884 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gene mutation'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, ETOPOSIDE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN, PACLITAXEL, PANITUMUMAB | DrugsGivenReaction | CC BY-NC | 33197299 | 18,711,884 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant neoplasm progression'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastatic squamous cell carcinoma'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, ETOPOSIDE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN, PACLITAXEL, PANITUMUMAB | DrugsGivenReaction | CC BY-NC | 33197299 | 18,711,884 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neuroendocrine carcinoma metastatic'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, ETOPOSIDE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN, PACLITAXEL, PANITUMUMAB | DrugsGivenReaction | CC BY-NC | 33197299 | 18,711,884 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neuroendocrine carcinoma'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Squamous cell carcinoma'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, ETOPOSIDE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN, PACLITAXEL, PANITUMUMAB | DrugsGivenReaction | CC BY-NC | 33197299 | 18,711,884 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic response decreased'. | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
What was the dosage of drug 'BEVACIZUMAB'? | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | UNK(4 COURSES) | DrugDosageText | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
What was the dosage of drug 'FLUOROURACIL'? | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | UNK(4 COURSES) | DrugDosageText | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
What was the dosage of drug 'IRINOTECAN'? | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | UNK(4 COURSES) | DrugDosageText | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
What was the dosage of drug 'LEUCOVORIN CALCIUM'? | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | UNK(4 COURSES) | DrugDosageText | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
What was the dosage of drug 'OXALIPLATIN'? | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | UNK(4 COURSES) | DrugDosageText | CC BY-NC | 33197299 | 18,952,120 | 2021-01 |
What was the outcome of reaction 'Death'? | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search reveale... | Fatal | ReactionOutcome | CC BY-NC | 33197299 | 18,711,884 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adrenocorticotropic hormone deficiency'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthritis'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Asthma'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bile duct stone'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cholangitis'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Colitis'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Eosinophilic fasciitis'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatitis'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infectious pleural effusion'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infusion related reaction'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Latent tuberculosis'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myocarditis'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nephritis'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonitis'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rhinitis allergic'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thyroid disorder'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Uveitis'. | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | ATEZOLIZUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33201587 | 18,564,141 | 2021-01 |
What was the outcome of reaction 'Pneumonitis'? | Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Non-small cell lung cancer (NSCLC) patients with pre-existing respiratory diseases have been excluded in clinical trials of ... | Fatal | ReactionOutcome | CC BY | 33201587 | 18,564,141 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Basal cell carcinoma'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cytomegalovirus infection reactivation'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Eczema'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastroenteritis'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Genitourinary tract infection'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Injection site reaction'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oral papilloma'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oropharyngeal candidiasis'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Psoriasis'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory tract infection'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic response decreased'. | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | GOLIMUMAB, MESALAMINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
What was the administration route of drug 'GOLIMUMAB'? | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.
This study aimed to describe the long-term outcomes in a large cohort ... | Subcutaneous | DrugAdministrationRoute | CC BY-NC-ND | 33203342 | 18,572,703 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diabetes mellitus inadequate control'. | Alopecia areata universalis under treatment with sitagliptin : Possible immunological effect of dipeptidyl peptidase-4 inhibitors?
A 64-year old man developed alopecia universalis after one month of treatment with metformin and sitagliptin, a dipeptidyl peptidase‑4 (DPP-4) inhibitor. Diabetes treatment was changed to a... | CANDESARTAN, DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, SITAGLIPTIN | DrugsGivenReaction | CC BY | 33205256 | 18,647,979 | 2021-07 |
What was the administration route of drug 'CANDESARTAN'? | Alopecia areata universalis under treatment with sitagliptin : Possible immunological effect of dipeptidyl peptidase-4 inhibitors?
A 64-year old man developed alopecia universalis after one month of treatment with metformin and sitagliptin, a dipeptidyl peptidase‑4 (DPP-4) inhibitor. Diabetes treatment was changed to a... | Oral | DrugAdministrationRoute | CC BY | 33205256 | 18,647,979 | 2021-07 |
What was the administration route of drug 'DAPAGLIFLOZIN'? | Alopecia areata universalis under treatment with sitagliptin : Possible immunological effect of dipeptidyl peptidase-4 inhibitors?
A 64-year old man developed alopecia universalis after one month of treatment with metformin and sitagliptin, a dipeptidyl peptidase‑4 (DPP-4) inhibitor. Diabetes treatment was changed to a... | Oral | DrugAdministrationRoute | CC BY | 33205256 | 18,647,979 | 2021-07 |
What was the outcome of reaction 'Alopecia universalis'? | Alopecia areata universalis under treatment with sitagliptin : Possible immunological effect of dipeptidyl peptidase-4 inhibitors?
A 64-year old man developed alopecia universalis after one month of treatment with metformin and sitagliptin, a dipeptidyl peptidase‑4 (DPP-4) inhibitor. Diabetes treatment was changed to a... | Not recovered | ReactionOutcome | CC BY | 33205256 | 18,657,448 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dry gangrene'. | Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient.
COVID-19 is an infectious disease caused by SARS-CoV-2. This enveloped RNA coronavirus primarily has tropism for the respiratory tract. However, it has also been shown to have various extrapulmonary manifestations such as pulmonary embolism... | ATORVASTATIN, HEPARIN SODIUM, INSULIN NOS, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 33205744 | 19,418,771 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary embolism'. | Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient.
COVID-19 is an infectious disease caused by SARS-CoV-2. This enveloped RNA coronavirus primarily has tropism for the respiratory tract. However, it has also been shown to have various extrapulmonary manifestations such as pulmonary embolism... | ATORVASTATIN, HEPARIN SODIUM, INSULIN NOS, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 33205744 | 19,418,771 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulseless electrical activity'. | Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient.
COVID-19 is an infectious disease caused by SARS-CoV-2. This enveloped RNA coronavirus primarily has tropism for the respiratory tract. However, it has also been shown to have various extrapulmonary manifestations such as pulmonary embolism... | ATORVASTATIN, HEPARIN SODIUM, INSULIN NOS, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 33205744 | 19,418,771 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient.
COVID-19 is an infectious disease caused by SARS-CoV-2. This enveloped RNA coronavirus primarily has tropism for the respiratory tract. However, it has also been shown to have various extrapulmonary manifestations such as pulmonary embolism... | ATORVASTATIN, HEPARIN SODIUM, INSULIN NOS, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 33205744 | 19,418,771 | 2021-01 |
What was the administration route of drug 'INSULIN NOS'? | Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient.
COVID-19 is an infectious disease caused by SARS-CoV-2. This enveloped RNA coronavirus primarily has tropism for the respiratory tract. However, it has also been shown to have various extrapulmonary manifestations such as pulmonary embolism... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33205744 | 19,397,730 | 2021-01 |
What was the outcome of reaction 'Dry gangrene'? | Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient.
COVID-19 is an infectious disease caused by SARS-CoV-2. This enveloped RNA coronavirus primarily has tropism for the respiratory tract. However, it has also been shown to have various extrapulmonary manifestations such as pulmonary embolism... | Not recovered | ReactionOutcome | CC BY | 33205744 | 19,418,771 | 2021-01 |
What was the outcome of reaction 'Pulmonary embolism'? | Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient.
COVID-19 is an infectious disease caused by SARS-CoV-2. This enveloped RNA coronavirus primarily has tropism for the respiratory tract. However, it has also been shown to have various extrapulmonary manifestations such as pulmonary embolism... | Fatal | ReactionOutcome | CC BY | 33205744 | 19,418,771 | 2021-01 |
What was the outcome of reaction 'Pulseless electrical activity'? | Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient.
COVID-19 is an infectious disease caused by SARS-CoV-2. This enveloped RNA coronavirus primarily has tropism for the respiratory tract. However, it has also been shown to have various extrapulmonary manifestations such as pulmonary embolism... | Fatal | ReactionOutcome | CC BY | 33205744 | 19,418,771 | 2021-01 |
What was the outcome of reaction 'Treatment failure'? | Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient.
COVID-19 is an infectious disease caused by SARS-CoV-2. This enveloped RNA coronavirus primarily has tropism for the respiratory tract. However, it has also been shown to have various extrapulmonary manifestations such as pulmonary embolism... | Fatal | ReactionOutcome | CC BY | 33205744 | 19,418,771 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dizziness'. | Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
Rapid restoration of sinus rhythm using pharmacological cardioversion is commonly indicated in patients with symptomatic recent-onset atrial fibrillation (AF). The objectives of this large, international, multicent... | FLECAINIDE, VERNAKALANT | DrugsGivenReaction | CC BY | 33206300 | 19,673,350 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
Rapid restoration of sinus rhythm using pharmacological cardioversion is commonly indicated in patients with symptomatic recent-onset atrial fibrillation (AF). The objectives of this large, international, multicent... | FLECAINIDE, VERNAKALANT | DrugsGivenReaction | CC BY | 33206300 | 19,673,350 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug interaction'. | Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
Rapid restoration of sinus rhythm using pharmacological cardioversion is commonly indicated in patients with symptomatic recent-onset atrial fibrillation (AF). The objectives of this large, international, multicent... | FLECAINIDE, VERNAKALANT | DrugsGivenReaction | CC BY | 33206300 | 19,695,564 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sinus arrest'. | Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
Rapid restoration of sinus rhythm using pharmacological cardioversion is commonly indicated in patients with symptomatic recent-onset atrial fibrillation (AF). The objectives of this large, international, multicent... | FLECAINIDE, VERNAKALANT | DrugsGivenReaction | CC BY | 33206300 | 19,695,564 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
Rapid restoration of sinus rhythm using pharmacological cardioversion is commonly indicated in patients with symptomatic recent-onset atrial fibrillation (AF). The objectives of this large, international, multicent... | FLECAINIDE, VERNAKALANT | DrugsGivenReaction | CC BY | 33206300 | 19,695,564 | 2021-04 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.